Neuland Laboratories quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	642	293	+119.2%
EBITDA	223	34.5	+546.3%
EBITDA margin	34.7%	11.8%	+23.0 pts
Profit before tax	198	17.6	+1,026.0%
Net profit	148	13.9	+962.4%
EPS	₹115.10	₹10.83	+962.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	642	776	440	514	293	328	398	311	440	385	393	418	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	8.5	12.5	8.1	1.8	7.9	7.5	3.9	4.3	4.8	5.4	2.1	3.0
	650	789	448	516	301	336	402	315	444	390	395	421
	229	231	200	228	161	141	145	133	155	175	153	139
	−7.7	38.5	−10.8	−44.0	−47.9	−14.3	20.9	−15.7	21.9	−37.5	−11.2	12.8
	106	98.5	88.8	80.4	73.5	66.5	69.3	63.1	73.1	62.5	65.7	69.0
	7.0	7.2	6.8	5.4	4.6	2.3	2.2	1.1	2.7	3.6	3.7	4.4
	26.6	25.1	23.9	22.5	20.2	16.9	16.3	16.1	16.3	16.5	15.1	14.5
	91.2	101	84.7	94.7	71.3	83.9	75.7	68.1	66.2	78.1	63.6	59.4
	452	501	393	387	283	297	330	266	335	298	290	299
	223	307	77.1	156	34.5	51.1	86.6	62.2	123	107	121	137
	196	282	53.2	133	14.3	34.2	70.3	46.2	107	90.5	106	123
Profit
	198	287	54.5	129	17.6	39.3	72.0	49.4	109	92.2	104	122
	0.0	0.0	0.0	0.0	0.0	0.0	55.8	0.0	20.6	0.0	0.0	0.0
	198	287	54.5	129	17.6	39.3	128	49.4	130	92.2	104	122
	50.9	76.8	15.3	32.5	4.4	6.0	25.0	12.2	30.6	22.0	25.3	31.4
	−0.7	−2.0	−1.4	0.1	−0.7	5.5	1.2	4.4	1.4	2.6	−2.2	0.9
	50.2	74.8	13.9	32.6	3.7	11.5	26.2	16.6	32.0	24.6	23.1	32.3
	148	213	40.6	96.9	13.9	27.8	102	32.8	97.9	67.6	81.4	89.2
	148	213	40.6	96.9	13.9	27.8	102	32.8	97.9	67.6	81.4	89.2
	−0.1	1.2	−0.2	−0.1	0.1	0.2	−0.0	−0.2	−0.0	0.9	0.1	0.4
	148	214	40.4	96.7	14.0	28.0	102	32.6	97.9	68.5	81.5	89.7
	148	213	40.6	96.9	13.9	27.8	102	32.8	97.9	67.6	81.4	—
Per share
	₹115.10	₹165.76	₹31.62	₹75.49	₹10.83	₹21.67	₹79.18	₹25.60	₹76.28	₹52.66	₹63.44	₹69.56
	₹115.10	₹165.76	₹31.62	₹75.49	₹10.83	₹21.67	₹79.18	₹25.60	₹76.28	₹52.66	₹63.44	₹69.56
Other comprehensive income — detail
	−0.1	1.2	−0.2	−0.1	0.1	0.2	—	—	—	—	—	—
	—	1.1	−0.2	−0.4	—	0.2	0.0	−0.5	0.0	1.0	0.0	0.4
	—	0.3	−0.1	−0.1	0.0	0.1	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	−0.1	0.0	0.0	0.0	0.0
	—	0.4	0.0	0.2	0.1	0.0	−0.0	0.2	—	—	—	—
	0.1	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	0.0	0.1	−0.1	−0.0
	148	214	40.4	96.9	14.0	27.8	102	32.8	97.9	67.6	81.4	—
Per share — as-filed variants
	₹115.10	₹165.76	₹31.62	₹75.49	₹10.83	₹21.67	₹79.18	₹25.60	₹76.28	₹52.66	₹63.44	₹69.56
	₹115.10	₹165.76	₹31.62	₹75.49	₹10.83	₹21.67	₹79.18	₹25.60	₹76.28	₹52.66	₹63.44	₹69.56
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	421	507	251	331	179	201	232	193	263	247	251	266
	65.5%	65.3%	57.0%	64.3%	61.2%	61.4%	58.2%	62.2%	59.8%	64.3%	63.8%	63.6%
Adjusted (ex-exceptional items) — derived
	198	287	54.5	129	17.6	39.3	72.0	49.4	109	92.2	104	122
	0.0	0.0	0.0	0.0	0.0	0.0	55.8	0.0	20.6	0.0	0.0	0.0
	148	213	40.6	96.9	13.9	27.8	57.2	32.8	82.3	67.6	81.4	89.2
	₹115.10	₹165.76	₹31.62	₹75.49	₹10.83	₹21.67	₹44.61	₹25.60	₹64.16	₹52.66	₹63.44	₹69.56

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NEULANDLAB₹19,970.00

Neuland Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB LAURUSLABS NH NATCOPHARM LALPATHLAB SAILIFE COHANCE ASTERDMMcap ₹25,762 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	417.7	392.8	385.0	439.6	310.8	398.0	328.4	292.8	514.3	439.7	776.3	641.6
Other Income	3.0	2.1	5.4	4.8	4.3	3.9	7.5	7.9	1.8	8.1	12.5	8.5
Total Income	420.8	394.9	390.4	444.4	315.2	401.9	335.8	300.6	516.1	447.8	788.7	650.1
Expenses
+ Cost of Materials Consumed	139.1	153.5	175.0	155.0	133.2	145.4	141.2	161.5	227.6	199.9	230.8	228.8
+ Changes in Inventories	12.8	-11.2	-37.5	21.9	-15.7	20.9	-14.3	-47.9	-44.0	-10.8	38.5	-7.7
+ Employee Benefit Expense	69.0	65.7	62.5	73.1	63.1	69.3	66.5	73.5	80.4	88.8	98.5	106.4
+ Finance Costs	4.4	3.7	3.6	2.7	1.1	2.2	2.3	4.6	5.4	6.8	7.2	7.0
+ Depreciation & Amortisation	14.5	15.1	16.5	16.3	16.1	16.3	16.9	20.2	22.5	23.9	25.1	26.6
+ Other Expenses	59.4	63.6	78.1	66.2	68.1	75.7	83.9	71.3	94.7	84.7	101.2	91.2
Total Expenses	299.2	290.4	298.2	335.2	265.8	330.0	296.5	283.0	386.6	393.3	501.2	452.2
EBITDA	137.5	121.3	106.9	123.4	62.2	86.6	51.1	34.5	155.5	77.1	307.3	222.9
EBIT	123.0	106.1	90.5	107.1	46.2	70.3	34.2	14.3	133.0	53.2	282.2	196.3
Profit
PBT before Exceptional Items	121.6	104.5	92.2	109.2	49.4	72.0	39.3	17.6	129.4	54.5	287.5	197.8
+ Exceptional Items	0.0	0.0	0.0	20.6	0.0	55.8	0.0	0.0	0.0	0.0	0.0	0.0
Pretax Income	121.6	104.5	92.2	129.8	49.4	127.8	39.3	17.6	129.4	54.5	287.5	197.8
+ Current Tax	31.4	25.3	22.0	30.6	12.2	25.0	6.0	4.4	32.5	15.3	76.8	50.9
+ Deferred Tax	0.9	-2.2	2.6	1.4	4.4	1.2	5.5	-0.7	0.1	-1.4	-2.0	-0.7
Tax Expense	32.3	23.1	24.6	32.0	16.6	26.2	11.5	3.7	32.6	13.9	74.8	50.2
Net Income	89.2	81.4	67.6	97.9	32.8	101.6	27.8	13.9	96.9	40.6	212.7	147.7
+ Net Income — Continuing Ops	89.2	81.4	67.6	97.9	32.8	101.6	27.8	13.9	96.9	40.6	212.7	147.7
+ Other Comprehensive Income	0.4	0.1	0.9	-0.0	-0.2	-0.0	0.2	0.1	-0.1	-0.2	1.2	-0.1
Total Comprehensive Income	89.7	81.5	68.5	97.9	32.6	101.6	28.0	14.0	96.7	40.4	213.9	147.6
Net Income to Common	—	81.4	67.6	97.9	32.8	101.6	27.8	13.9	96.9	40.6	212.7	147.7
Per Share
Basic EPS	69.56	63.44	52.66	76.28	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10
Diluted EPS	69.56	63.44	52.66	76.28	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.2	0.1	-0.1	-0.2	1.2	-0.1
+ Items NOT to be Reclassified to P&L	0.4	0.0	1.0	0.0	-0.5	0.0	0.2	—	-0.4	-0.2	1.1	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.1	0.0	-0.1	-0.1	0.3	—
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	0.0	0.0	-0.1	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	0.2	-0.0	0.0	0.1	0.2	0.0	0.4	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.1
+ Tax on Items to be Reclassified — alt tag	-0.0	-0.1	0.1	0.0	0.0	0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	—	81.4	67.6	97.9	32.8	101.6	27.8	14.0	96.9	40.4	213.9	147.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	69.56	63.44	52.66	76.28	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10
Diluted EPS — Continuing Operations	69.56	63.44	52.66	76.28	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	265.8	250.6	247.5	262.7	193.4	231.6	201.5	179.2	330.7	250.7	507.0	420.6
Gross Margin %	63.64	63.79	64.28	59.76	62.21	58.20	61.35	61.22	64.30	57.00	65.31	65.55
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	121.6	104.5	92.2	109.2	49.4	72.0	39.3	17.6	129.4	54.5	287.5	197.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	20.6	0.0	55.8	0.0	0.0	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	89.2	81.4	67.6	82.3	32.8	57.2	27.8	13.9	96.9	40.6	212.7	147.7
EPS Adj	69.56	63.44	52.66	64.16	25.60	44.61	21.67	10.83	75.49	31.62	165.76	115.10
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	—	12.9	12.9	12.9	12.9	12.9	12.9	12.9	12.9	12.9	12.9	12.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Neuland Laboratories Q2 FY27 results date

Neuland Laboratories (NSE: NEULANDLAB) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 22 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹148 crore, up 962.4% from ₹13.9 crore in Q1 FY26 and down 30.6% from ₹213 crore in Q4 FY26. Revenue from operations was ₹642 crore, up 119.2% year on year and down 17.3% from the previous quarter.

Board-meeting notice filed: 22 October 2026
Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 5 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 22 Oct
Q1 FY27 net profit: ₹148 Cr+962.4% vs Q1 FY26−30.6% vs Q4 FY26
Q1 FY27 revenue: ₹642 Cr+119.2% vs Q1 FY26−17.3% vs Q4 FY26
Q1 FY27 operating margin: 30.6%+25.7 pts vs Q1 FY26−5.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹96.9 CrRevenue ₹514 Cr
Q1 FY27 EPS (basic): ₹115.10

Questions

When will Neuland Laboratories announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 22 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What was Neuland Laboratories' net profit in FY26?

Consolidated net profit was ₹364 crore in FY26 (April 2025–March 2026), up 39.9% from ₹260 crore in FY25. It was ₹300 crore in FY24 and ₹164 crore in FY23: up 122.6% over three years, 30.6% a year on average.

What was Neuland Laboratories' revenue in FY26?

Revenue from operations was ₹2,023 crore in FY26 (April 2025–March 2026), up 37.0% from ₹1,477 crore in FY25. It was ₹1,559 crore in FY24 and ₹1,191 crore in FY23: up 69.8% over three years, 19.3% a year on average.

What will Neuland Laboratories' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹96.9 crore and revenue from operations ₹514 crore. The latest quarter, Q1 FY27, had a net profit of ₹148 crore and revenue of ₹642 crore.

What were Neuland Laboratories' Q1 FY27 results?

Consolidated net profit was ₹148 crore, up 962.4% from ₹13.9 crore in Q1 FY26 and down 30.6% from ₹213 crore in Q4 FY26. Revenue from operations was ₹642 crore, up 119.2% year on year and down 17.3% from the previous quarter.

How has Neuland Laboratories' profit changed over the last four quarters?

Net profit by quarter: ₹96.9 crore in Q2 FY26, ₹40.6 crore in Q3 FY26, ₹213 crore in Q4 FY26 and ₹148 crore in Q1 FY27. That is ₹498 crore over the four quarters, up 182.6% from ₹176 crore in the four quarters before. Revenue from operations: ₹514 crore, ₹440 crore, ₹776 crore and ₹642 crore.

Where do these Neuland Laboratories figures come from?

From Neuland Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.